Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
Subscribe To Our Newsletter & Stay Updated
